Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test IDH1 & IDH2 Gene Analysis Test by NGS (Hotspot Regions) is typically 14-21 days from the date of sample receipt at the laboratory.

What are the prerequisites for the test IDH1 & IDH2 Gene Analysis Test by NGS (Hotspot Regions)

  • Patient must have a suspected diagnosis of glioma or acute myeloid leukemia
  • Specimen must be formalin-fixed paraffin-embedded tissue or bone marrow
  • Specimen must be sent to a certified laboratory for testing
  • Patient must not have received chemotherapy or radiation therapy within the past 2 weeks
  • Physician must provide a detailed clinical history and relevant medical records

What are the measure values for the test IDH1 & IDH2 Gene Analysis Test by NGS (Hotspot Regions)

  • IDH1 Gene Analysis:
    • Hotspot Regions:
      • R132 (exon 4)
  • IDH2 Gene Analysis:
    • Hotspot Regions:
      • R140 (exon 4)
      • R172 (exon 4)

What does this test IDH1 & IDH2 Gene Analysis Test by NGS (Hotspot Regions) identify?

Test IDH1 & IDH2 Gene Analysis Test by NGS (Hotspot Regions)

This test is used to identify mutations in the IDH1 and IDH2 genes through Next Generation Sequencing (NGS) technology. The IDH1 and IDH2 genes encode for enzymes that play a role in cellular metabolism. Mutations in these genes have been associated with various types of cancer, including gliomas, acute myeloid leukemia (AML), and chondrosarcomas.

By analyzing the hotspot regions of the IDH1 and IDH2 genes, this test can detect specific mutations that may be driving the development of cancer. This information can help clinicians make informed decisions about treatment options and prognosis for patients with cancer.

Why is this test IDH1 & IDH2 Gene Analysis Test by NGS (Hotspot Regions) taken?

The IDH1 & IDH2 Gene Analysis Test by NGS (Hotspot Regions) is taken to detect mutations in the IDH1 and IDH2 genes. These genes encode enzymes that play a role in cell metabolism. Mutations in these genes have been associated with various types of cancer, including gliomas, acute myeloid leukemia, and chondrosarcomas.

By analyzing the hotspot regions of the IDH1 and IDH2 genes using Next Generation Sequencing (NGS), healthcare providers can determine if a patient has a mutation that may be driving their cancer. This information can help guide treatment decisions, as some mutations may respond better to specific targeted therapies.

No FAQs available.

Customer Google Rating